MS, Multiple Sclerosis
Conditions
Keywords
RebiSmart, Rebif, Adherence, Multidose, Relapsing Multiple Sclerosis, RMS
Brief summary
This is a multi-center, two-arm non-comparative, observational, 96 week Phase IV study to evaluate treatment adherence when using RebiSmart™ for self-injection of Rebif® in subjects with relapsing multiple sclerosis (RMS). Subjects who have a confirmed diagnosis of RMS using McDonald Criteria and meet the eligibility criteria during a screening period of up to 28 days will be provided with an electronic self-injection device (RebiSmart™) to inject Rebif® for 96 weeks. The main purpose of this study is to evaluate treatment adherence for subjects with RMS over 24 weeks of treatment when using RebiSmart™ for self-injection of Rebif® in a multi-dose cartridge.
Interventions
DEVICERebiSmart™
Electronic self-injection device (RebiSmart™) to inject Rebif®
Sponsors
EMD Inc., Canada
Merck KGaA, Darmstadt, Germany
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Males and females between 18 and 65 years of age. * Have RMS according to the revised McDonald Criteria. * Subject is eligible for Rebif® therapy according to indications and clinical use in the Rebif® Product Monograph. * Be willing and able to comply with the protocol requirements for the duration of the study. * Have given written informed consent prior to entering the screening period. * Must register with the Rebif® Multiple Support Program. * Subjects previously on disease modifying drugs (DMDs) must be stable and not be experiencing any side effects related to the previous DMDs at the time of enrollment into the study, in the opinion of the investigator. Rebif® will be prescribed as per Product Monograph and a washout period will be left at the discretion of the investigator.
Exclusion criteria
* Have any disease other than MS that could better explain his/her signs and symptoms. * Receive any other injectable medications on a regular basis during the week prior to the screening period or throughout the duration of the study. The administration of a single injection for treatment or prophylaxis of a condition unrelated to the subject's MS (e.g.,influenza or pneumococcus vaccination) will be acceptable. * Are contraindicated for the use of Rebif® according to the Rebif® Product Monograph. * Have a diagnosis of clinically isolated syndrome (CIS). * Participation in any other investigational trial prior to 30 days of Study Day 1. * Any visual or physical impairment that precludes the subject from self-injecting the treatment using RebiSmart™ * Have received previous treatment with Rebif within 5 years prior to screening. * Subjects have any medical, psychiatric or other conditions that compromise his/her ability to understand the subject information, to give informed consent, to comply with the study protocol or to complete the study questionnaires.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment adherence for RMS subjects over 24 weeks of treatment when using RebiSmart™ for self-injection of Rebif® in a multi-dose cartridge. | 24 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Treatment persistence by measuring treatment discontinuations | 96 weeks | — |
| Treatment compliance | 96 weeks | Measuring the number of injections received relative to the time on study |
| Long-term adherence in subjects with RMS over 96 weeks of treatment using RebiSmart for self-injection of Rebif® in multi-dose cartridge. | 96 weeks | — |
| Longitudinal changes in anxiety symptoms | 96 weeks | Measured by the Hospital Anxiety and Depression Scale (HAD) and State-Trait Anxiety Inventory (STAI) |
| Qualitative assessment of subjects' experience with RebiSmart | 96 weeks | A standardized Patient Experience Questionnaire (PEQ) will be used for the assessment. |
| Comparison of subject treatment adherence between categories of cognitive function | 96 weeks | Measured by the short version of Rao's Brief Repeatable Battery (BRB) |
Countries
Canada
Outcome results
None listed